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Objectives The SPIRIT V (A Clinical Evaluation of the XIENCE V Everolimus-Eluting Coronary Stent
System in the Treatment of Patients With De Novo Coronary Artery Lesions) study is a post-market
surveillance experience of the XIENCE V (Abbott Vascular, Santa Clara, California) everolimus-eluting
stent (EES) in patients with higher-risk coronary anatomy.
Background Previous pre-approval studies have shown the safety and efﬁcacy of EES in highly se-
lected groups of patients.
Methods The SPIRIT V trial is a prospective, open label, single arm, multicenter study. Two thousand seven
hundred patients with multiple de novo coronary artery lesions suitable for treatment with a planned maxi-
mum of 4 EES were enrolled at 93 centers in Europe, Asia Paciﬁc, Canada, and South Africa. Lesions had a
reference vessel diameter between 2.25 and 4.0 mm and a length of 28 mm by visual estimation. An inde-
endent clinical events committee adjudicated all end point-related events. The primary end point was the
omposite rate of all death, myocardial infarction (MI), and target vessel revascularization at 30 days. Second-
ry end points included stent thrombosis and acute success (clinical device and procedure success).
esults At 30 days, the primary composite end point of all death, MI, and target vessel revascularization was
.7%. At 1 year, rates of cardiac death, overall MI, and target lesion revascularization were 1.1%, 3.5%, and
.8%, respectively. The cumulative rate of deﬁnite and probable stent thrombosis was low at 0.66% at 1 year.
onclusions Use of EES in patients with multiple, complex de novo lesions yielded 1-year major ad-
erse cardiac events, stent thrombosis, and target lesion revascularization rates that are comparable to
hose of the more controlled SPIRIT II and SPIRIT III trials—which included patients with restricted inclu-
ion/exclusion criteria—and other all-comer population, physician-initiated studies like the X-SEARCH
Xience Stent Evaluated At Rotterdam Cardiology Hospital) and COMPARE (A Randomized Controlled
rial of Everolimus-eluting Stents and Paclitaxel-eluting Stents for Coronary Revascularization in Daily
ractice) trials. (J Am Coll Cardiol Intv 2011;4:168–75) © 2011 by the American College of Cardiology
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169Stenting of de novo lesions in native coronary arteries has
been shown to be a safe and effective treatment of coronary
atherosclerosis. The application of antiproliferative drugs to
the stent is believed to decrease the need for patients to
undergo repeat percutaneous coronary intervention (PCI) or
coronary artery bypass graft (CABG). Drug-eluting stents
are used in approximately 50% of procedures in Europe and
the U.S. (1).
The feasibility and efficacy of the XIENCE V (Abbott
Vascular, Santa Clara, California) everolimus-eluting
stent (EES) was investigated for the first time in the
SPIRIT FIRST (A Clinical Evaluation of an Investiga-
tional Device. The Abbott XIENCE V Everolimus Eluting
Coronary Stent System in the Treatment of Patients With de
Novo Native Coronary Artery Lesions) trial (n  60). In this
multicenter, single-blind, controlled study the EES was com-
pared with the uncoated MULTI-LINK VISION RX coro-
nary stent (Abbott Vascular) in patients with native de novo
coronary artery disease and showed a significant reduction in
angiographic in-stent late loss for the EES, relative to the
bare-metal stent at 6 and 12 months (2). This was continued
out to 5 years without additional target vessel failure events and
no very late stent thromboses reported between 1- and
5-year follow-up in the EES arm (3). The EES was further
evaluated in the SPIRIT II (4) and SPIRIT III trials (5)—2
randomized comparisons against the TAXUS paclitaxel-
eluting stent (PES)—both of which suggested superior clinical
outcomes out to 2 years with the EES. Both trials had
restrictive angiographic inclusion criteria. The aim of the
SPIRIT V study was to continue the assessment of the EES in
patients with higher-risk anatomy outside the restrictive inclu-
sion/exclusion criteria used in the SPIRIT II and SPIRIT III
trials. In this manuscript we report the 30-day and 1-year
clinical results of this study.
Methods
Patient selection. This prospective open-label single-arm
ulticenter study was conducted in 93 clinical sites in
everal countries in Europe and Asia, also including India,
anada, South Africa, and New Zealand (Online Appen-
ix). Two thousand seven hundred patients were enrolled
etween November 2006 and November 2007. The study
rotocol was approved by the medical ethics committee of
ach participating site before patient enrollment. A prospec-
ive single-blind double-arm randomized multicenter sub-
tudy, in which diabetic patients were randomized in a 2:1
atio (EES vs. PES), will be reported separately.
Patients were recruited from the general interventional
ardiology population who had been admitted for a PCI
rocedure. Inclusion criteria were according to the instruc-
ions for use, which included patients with age 18 years,
vidence of myocardial ischemia, stable or unstable angina,
nd silent ischemia or a positive functional study or aeversible change in the electrocardiogram consistent with
schemia. Patients were also required to be acceptable for
ABG surgery and had to agree to undergo all protocol-
equired follow-up examinations. Coronary anatomy had to
e suitable for optimal planned treatment with a maximum
f 4 planned EES in de novo target lesions with a vessel
eference diameter between 2.25 and 4.0 mm and a lesion
ength of 28 mm by visual estimation. Patients were not
ligible if they had participated in another device or drug
tudy or had completed the follow-up phase of another
tudy within 30 days before enrollment. Eligible patients
ere asked to provide informed consent, as approved by the
ocal medical ethics committee of each clinical site. Patients
eeting the general inclusion/exclusion criteria were asked
o provide informed consent and
ere to be entered into the screen-
ng log, whether enrolled in the
tudy or not. Screening failures
ccounted for 13.6% of the total
atients entered in the screening
og (425 of 3,125).
EES. Details of the device have
been published previously (2,4).
Briefly, the study device, the
XIENCE V EES (Abbott Vascu-
lar, Santa Clara, California), com-
prises the MultiLink VISION
stent or the ML MINI VISION
stent on a delivery system with a
drug-eluting coating. The ML
VISION stent is a balloon-
expandable stent, which consists
of serpentine rings connected by
links fabricated from a single piece
of medical-grade L–605 cobalt
chromium alloy. The drug coating
is composed of 2 polymers and the
antiproliferative drug everolimus.
Everolimus is blended in a non-
erodable polymer, coated over an-
other non-erodable polymer primer layer. The coating com-
prises acrylic and fluorinated copolymers, both approved for
use in blood-contacting applications. Everolimus (Certican,
Novartis Pharmaceuticals, Basel, Switzerland) is a drug that
has been approved for use in conjunction with other medica-
tions to prevent heart and renal transplant rejection in many
countries worldwide.
Procedural information. Patients were registered via an in-
teractive voice response system (ICON Clinical Research,
Eastleigh, United Kingdom) after confirmation of the
angiographic inclusion criteria and successful pre-dilation of
the first target lesion. Registered patients were considered
enrolled in the study and were to remain in the study until
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
CABG  coronary artery
bypass grafting
CI  confidence interval
EES  everolimus-eluting
stent(s)
ITT  intent-to-treat
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
QCA  quantitative coronary
angiography
ST  stent thrombosis
TLF  target lesion failure
TLR  target lesion
revascularization
TVR  target vessel
revascularizationcompletion of the required follow-up period. The process of
a
A
a
d
i
d
a

C
p
u
t
A
i
s
p
t
c
d
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 2 , 2 0 1 1
F E B R U A R Y 2 0 1 1 : 1 6 8 – 7 5
Grube et al.
The SPIRIT V Study: Clinical Evaluation of XIENCE V
170registration was designed to reduce investigator bias with
regard to enrollment and/or withdrawal of patients in the
study.
The stent was available in diameters of 2.25, 2.5, 2.75,
3.0, 3.5, and 4.0 mm and lengths of 8, 12, 15, 18, 23, and
28 mm. Treatment was with up to a maximum of 4 planned
study stents, depending on the number of vessels treated and
their respective lesion lengths. Overlapping stents were
required to have a minimum overlap of 1 mm and a
maximum of 4 mm. All target lesions were to be treated
with standard interventional techniques with mandatory
pre-dilation and stent implantation at a pressure not exceed-
ing the rated burst pressure. Post-dilation was left to the
discretion of the investigator; however, if performed, it was
only to be done with balloons sized to fit within the
boundaries of the stent. Brachytherapy in any lesion or
vessel or any other non-study percutaneous procedure was
not allowed at the time of the study procedure. In the event
of bailout and additional stent requirement, the EES were
to be used.
Periprocedural pharmacotherapy was administrated ac-
cording to standard hospital practice. Either unfractionated
heparin or bivalirudin was allowed for procedural anticoag-
ulation. The use of glycoprotein IIb/IIIa inhibitors was left
to the discretion of the investigator. All patients enrolled in
the study were to be pre-treated with a loading dose of
300 mg of clopidogrel. After the procedure, the protocol
recommended that patients receive clopidogrel 75 mg daily
for a minimum of 3 months with 75 mg of aspirin for a
minimum of 5 years.
Source document veriﬁcation. In the present study, source
document verification was routinely performed in 20% of
random cases and 100% of all reported adverse events at the
time of the study conduct, resulting in an overall rate of
30%. In addition, sites with low rates of reported events
received additional training and monitoring visits to confirm
event-reporting. Finally, all reported end points-related
events were adjudicated by an independent clinical events
committee that had access to source documentation.
Follow-up. Assessment of anginal status, collection of data
regarding adverse events, details of any subsequent coronary
interventions, Clinical Investigational Plan medications,
and use and changes in concomitant medications were
collected at 30 days (7 days) and 1 year (28 days).
Study end points. The primary end point was the adjudi-
cated composite rate of all death, myocardial infarction
(MI), and target vessel revascularization (TVR) at 30 days.
In addition to acute success including clinical device and
clinical procedure success, secondary end points included
adjudicated stent thrombosis (ST) and adjudicated cardiac
death, MI, and revascularization (target lesion revascular-
ization [TLR]/TVR/all revascularizations) rates. The adju-
dicated composite rates of cardiac death, MI not clearly
attributed to a nontarget vessel and TLR, and of all death, dMI, and any revascularization (TLR/TVR/non-TVR) were
reported at 30 days and at 1 year.
Deﬁnitions. All study end point events were adjudicated by
n independent clinical event committee according to the
cademic Research Consortium (ARC) definitions (6). All
dverse events were reported bimonthly to an independent
ata and safety monitoring board that reviewed data to
dentify any safety issues related to the conduct of the study.
DEATH. All deaths were considered cardiac unless an un-
equivocal noncardiac cause could be established. Specifi-
cally, any unexpected death, even in patients with coexisting
potentially fatal noncardiac disease (e.g., cancer, infection),
were classified as cardiac.
CARDIAC DEATH. Cardiac death was defined as any death
due to immediate cardiac cause (e.g., MI, low-output
failure, fatal arrhythmia). Unwitnessed death and death of
unknown cause were classified as cardiac death. This in-
cluded all procedure-related deaths including those related
to concomitant treatment.
MI. The MI classification and criteria for diagnosis were
efined according to the ARC as follows: for nonprocedur-
l/spontaneous MI, troponin or CK-MB levels had to be
2 upper limit of normal; for peri-PCI, troponin or
K-MB levels had to be 3 upper limit of normal; for
eri-CABG, troponin or CK-MB levels had to be 5
pper limit of normal. The periprocedural period included
he first 48 h and 72 h after PCI and CABG, respectively.
ll late events that were not associated with a revascular-
zation procedure were considered spontaneous. One blood
ample was taken from each patient within the post-
rocedure hospital stay period for the analysis of CK-MB or
roponin levels.
TLR. A TLR is defined as any repeat percutaneous inter-
vention of the target lesion or bypass surgery of the target
vessel performed for restenosis or other complication of the
target lesion. The target lesion is defined as the treated
segment from 5 mm proximal and 5 mm distal to the stent.
TVR. A TVR is defined as any repeat percutaneous inter-
vention or surgical bypass of any segment of the target
vessel. The latter is defined as the entire major coronary vessel
proximal and distal to the target lesion, including upstream and
downstream branches and the target lesion itself.
TARGET LESION FAILURE (TLF). TLF is defined as the
omposite of cardiac death, target vessel MI, or ischemia-
riven TLR (PCI or CABG).
ST. Stent thrombosis was categorized as acute (1 day),
subacute (1 to 30 days), and late (30 days) and was defined
according to the ARC guidelines as follows: definite: acute
coronary syndrome and angiographic or pathological con-
firmation of ST; probable: unexplained death 30 days or
target vessel MI without angiographic information; and
possible: unexplained death 30 days after stent placement.
CLINICAL DEVICE SUCCESS. Clinical device success wasefined as successful delivery and deployment of the study
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171stent (in an overlapping stent setting, a successful delivery
and deployment of the first and following study stent) at the
intended target lesion and successful withdrawal of the stent
delivery system with attainment of final residual stenosis of
50% of the target lesion by quantitative coronary angiog-
raphy (QCA) (by visual estimation if QCA unavailable),
without use of a device outside the assigned treatment
strategy. Bailout patients were included as clinical device
success only if the aforementioned criteria were met.
CLINICAL PROCEDURE SUCCESS. Clinical procedure success
was defined as successful delivery and deployment of the
study stent or stents at the intended target lesion and
successful withdrawal of the stent delivery system with
attainment of final residual stenosis of 50% of the target
lesion by QCA (by visual estimation if QCA unavailable)
and/or with any adjunctive device without the occurrence of
cardiac death, MI not clearly attributed to a nontarget
vessel, and/or clinically indicated TLR during the hospital
stay with a maximum of first 7 days after index procedure.
In a multiple lesions setting, each lesion must have met
clinical procedure success criteria.
Statistical analysis. All analyses were performed on the
intent-to-treat (ITT) population. The sample size for the
study was based on the primary end point of the composite
rate of all death, MI, and TVR at 30 days. A sample size of
2,700 patients would produce a narrow 2-sided 95% confi-
dence interval (CI) around the clinical end points estimates.
The one-half width of the 2-sided CI around the primary
end point would be between 0.6% and 0.9%, assuming a
true rate between 3% and 6%. Binary variables are presented
as percentages. Mean and SD are presented for continuous
variables.
Subgroup analysis with TLF as outcome is represented
with descriptive measurements (absolute percentage differ-
ence), 95% CI, and post hoc p value (with normal approx-
imation), with subgroups created according to sex: women
(n  580) versus men (n  2,020); vessel diameter: 2.75
mm (n  1,046) versus 2.75 mm (n  1,554); number of
target vessels treated: single vessel (n  2,125) versus
multiple vessels (n  475); lesion length: 20 mm (n 
89) versus 20 mm (n  1,711); diabetes status: patients
ith (n 768) versus patients without diabetes or unknown
iabetes status (n  1,832); and bifurcation C, D, F, G
esions: patients with (n  502) versus patients without C,
, F, G bifurcation lesions (n  2,098).
esults
A total of 2,700 patients were enrolled in the study. As
defined by the protocol, all results are presented for the ITT
population. Thirty-seven patient records were excluded
from the ITT population due to enrollment errors, lack of
informed consent, and/or no attempt to implant an EESduring the index procedure, leaving an ITT population of
2,663 patients (Fig. 1).
Baseline demographic data (Table 1) showed that 30% of
patients were diabetic, 82% of lesions were class B2 or C
classification according to the American College of Cardi-
ology/American Heart Association, and 29% of patients had
more than 1 target lesion treated.
Lesions, as assessed by the treating physician, had a mean
reference vessel diameter of 3.0 mm and mean lesion length
of 15.6 mm (Table 2). Most treated lesions were in the left
anterior descending artery (46%). Patients were treated
according to standard interventional techniques with high
acute device and procedure success rates (99% and 98%,
respectively). The mean number of lesions treated/patient
was 1.4, and the mean number of devices implanted was 1.5.
At 30  7 days, the primary end point of adjudicated
composite rate of all death, MI, and TVR was 2.7% (Table 3).
The overall death rate was 0.5%, and the MI rate was 2.2%
with 0.2% Q-wave MI and 2.0% non–Q-wave MI. Because
there was no angiographic follow-up in the study, all revascu-
larizations were considered ischemic-driven, and the TLR rate
at 30 days was 0.3%. At 1 year  28 days the composite rate
of cardiac death, MI not clearly attributed to a nontarget vessel,
and TLR was 5.1% (Fig. 2). The cardiac death rate was 1.1%,
the MI rate was 3.5%, and the rate of any revascularization was
5.9% (including TLR 1.8%, TVR (excluding TLR) 1.5%,
TVR (including TLR) 2.8%, and non-TVR 3.9%).
Figure 1. ITT Population Through 1 Year
A total of 2,700 patients with multiple de novo coronary artery lesions
were enrolled at 93 centers in Europe, Asia Paciﬁc, Canada, and South
Africa. A total of 37 patient records were excluded from the intent-to-treat
(ITT) population due to enrollment errors, lack of informed consent, and/or
no attempt to implant an everolimus-eluting stent during the index proce-
dure, leaving an ITT population of 2,663 patients. At 1 year, 3 patients had
withdrawn informed consent, 2 patients were withdrawn by the physician,
11 patients were lost to follow-up, and 50 patients missed the follow-up
visit, leaving a population of 2,597 patients.
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172Target lesion failure (defined as composite of cardiac
death, MI related to the target vessel, and TLR) rates at 1
year did not significantly differ between the high-risk
subgroups studied and their fewer complex counterparts,
with the exception of patients with multiple vessels treated
(Fig. 3). Patients with multivessel treatment had signifi-
cantly higher 1-year TLF rates compared with those who
had a single vessel treated (absolute difference: 3.06%, 95%
CI: 0.52% to 5.60%, p  0.011).
Table 1. Baseline Characteristics of the Intent-to-Treat Population
(n  2,663)
Age (yrs) 63 11
Men, n 78
Current tobacco use 24
All diabetes mellitus 30
Diabetes mellitus requiring medication 26
Diabetes mellitus requiring insulin 7
Hypertension requiring medication 64
Hypercholesterolemia requiring medication 59
All prior cardiac intervention 25
Prior cardiac intervention on target vessel(s) 9
Family history of coronary artery disease 34
MI within 2 months 13
Stable angina 46
Unstable angina 33
Silent ischemia 5
Number of diseased vessels
Single-vessel 58
Double-vessel 27
Triple or more vessels 14
Number of target lesions
1 71
2 22
3 5
Values are mean SD or %.
MImyocardial infarction.
Table 2. Procedural Characteristics (n  2,663)
Acute procedure success 98
Acute device success 99
LAD 46
LCX 25
RCA 28
Lesion class B2/C 82
Reference vessel diameter (mm) 3.0 0.4
Lesion length (mm) 15.6 6.2
Stented length (mm) 29.4 17.1
Number of target lesions 1.4 0.7
Stents implanted/patient 1.5 0.8
Most frequent stent length implanted (18.0 mm) 25
Most frequent stent diameter implanted (3.0 mm) 41
Values are % or mean  SD. Most frequent stent length and diameter are based on 4,091
implanted study stents. Reference vessel diameter and lesion length are based on 3,645 lesions.LAD left anterior descendingartery; LCX left circumflexartery; RCA right coronary artery.The definite and probable subacute and late ST rates at 1
year were 0.3% and 0.2%, respectively (Fig. 4). The cumu-
lative definite and probable ST rate to 1 year was 0.66%. At
1 year, 86% and 97% of patients were taking clopidogrel and
aspirin, respectively.
Discussion
The EES have been shown to be safe and effective in
randomized trials of carefully selected patients. The objec-
tive of the SPIRIT V trial was to evaluate whether this also
holds true in patients with more complex lesion types that
were selected under less-restrictive criteria and thus more
closely resembling the real-world situation. As investigator
reported, the population in the SPIRIT V trial included a
high proportion of complex patients, including 30% of
diabetic patients, 82% with class B2 or C lesions, and 29%
with more than 1 target lesion treated.
Our data show that, in this complex patient population,
the rates of cardiac death, MI, and TLR were low at 30 days
and remained low at 1 year. This is evidenced by the low
composite rate of cardiac death, target vessel-related MI,
TLR, late definite and probable ST, as well as cumulative
rates of ST out to 1 year. In addition, 1-year TLF rates in
complex patient subgroups did not significantly differ from
those observed in their fewer complex counterparts, with the
exception of the 1-year TLF rate in patients with multiple
vessels treated, which was significantly higher than that in
patients with a single vessel treated. Importantly, because
there was no angiographic follow-up, all revascularizations
Table 3. Major Adverse Cardiac Events at 30 Days and 1 Year in the
Intent-to-Treat Population
30 Days
(n  2,663)
1 Yr
(n  2,600)
Nonhierarchical events
All death 0.5 1.7
Cardiac death 0.4 1.1
Myocardial infarction 2.2 3.5
Q-wave 0.2 0.3
Non–Q-wave 2.0 3.2
TLR 0.3 1.8
TVR (non-TLR) 0.1 1.5
TVR (including TLR) 0.3 2.8
Non-TVR 0.9 3.9
Any revascularizations 1.2 5.9
Composite events
Composite all death, MI, and TVR 2.7 6.8
Composite cardiac death, MI (not clearly
attributed to non-TV), and TLR
2.5 5.1
Values are %.
MI  myocardial infarction; TLR  target lesion revascularization; TV  target vessel;TVR target vessel revascularization.
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173were considered ischemia-driven and not driven by the
result of a protocol-mandated catheterization procedure.
The rates of periprocedural MI were low, despite the use of
the ARC definitions allowing the use of troponin or
CK-MB levels for event adjudication.
The data presented here are in line with those previously
reported in the SPIRIT II and III studies with very
restricted enrollment criteria, allowing only patients with no
more than 2 de novo coronary artery lesions. At 1 year, the
SPIRIT II study reported major adverse cardiac events
(MACE) and cardiac death rates in EES-treated patients of
Figure 2. Kaplan-Meier Curve for Target Lesion Failure
Freedom from target lesion failure (cardiac death, myocardial infarction attribu
Figure 3. Subgroup Analysis of the 1-Year Target Lesion Failure Rates
The absolute differences in 1-year target lesion failure rates (deﬁned as the co
target lesion revascularization) are plotted for the different subgroups. Data w
length, bifurcation status, diabetes mellitus status, and sex. CI  conﬁdence interval2.7% and 0.0%, respectively (7), and clinical safety was
sustained at 2 years (8). In the SPIRIT III study, patients
treated with the EES had improved event-free survival,
TVF (8.6% vs. 11.3%, hazard ratio: 0.75, 95% CI: 0.49 to
1.14, p  0.18), and MACE (cardiac death, MI, or TLR;
6.0% vs. 10.3%, hazard ratio: 0.57, 95% CI: 0.36 to 0.90,
p  0.01) at 1-year follow-up (9).
The SPIRIT IV trial of 3,690 patients with up to 3 de
novo lesions reported a 1-year rate of TLF (cardiac death,
target vessel MI, and ischemia-driven TLR), the primary
end point, of 3.9% and ARC-defined definite and probable
the target vessel and target lesion revascularization) through 1 year.
te of cardiac death, myocardial infarction attributed to the target vessel and
atiﬁed according to number of target vessels treated, vessel diameter, lesionmposi
ere str.
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174ST of 0.29% as derived from Kaplan-Meier estimates and
log-rank test (10).
Although patients in the SPIRIT V trial were of a more
complex type, it can be argued whether they really reflect the
real-world patient population, because of the presence of
broad selection criteria. Interestingly, the X-SEARCH
(Xience Stent Evaluated At Rotterdam Cardiology Hospi-
tal) registry and the prospective randomized COMPARE
trial (A Randomized Controlled Trial of Everolimus-
eluting Stents and Paclitaxel-eluting Stents for Coronary
Revascularization in Daily Practice), both performed in an
all-comer population, recently reported an efficacy and
safety of the EES similar to those observed in the SPIRIT
V study. The X-SEARCH study showed subacute and late
definite ST rates of 0.3% and 0%, respectively, at 6-month
follow-up (11), whereas in the COMPARE trial at 1 year,
the rates of subacute and late ST were 0.1% and 0.4%,
respectively (12). The rates of cardiac death of 1.1% and MI
of 2.2% (of which 0.2% were Q-wave MI and 2% were
non–Q-wave MI) at 1-year follow-up in the SPIRIT V
study closely resemble those obtained in the COMPARE
trial (cardiac death: 2%; MI: 3%; Q-wave MI: 0.3%; and
non–Q-wave MI: 2%). The data obtained in the SPIRIT V
study support that of the real-world populations of the
X-SEARCH and COMPARE studies.
Registries of PCI using other drug-eluting stents have
shown results similar to the SPIRIT V study. The e-Cypher
Registry (13), a registry of 15,157 patients treated with the
sirolimus-eluting Cypher stent (Cordis Corporation, War-
ren, New Jersey) with no pre-specified inclusion or exclu-
sion criteria reported a MACE rate (all death, MI, and
TLR) of 1.36% at 30 days and 5.8% at 1 year. The 1-year
protocol-defined definite and likely cumulative ST rate was
0.87%. The WISDOM (Web-based TAXUS Interconti-
Figure 4. Definite and Probable Stent Thrombosis Rates to 1 Year
Stent thrombosis rates were deﬁned according to the Academic Research
Consortium guidelines (see Methods section) and were categorized as
acute (1 day), subacute (1 to 30 days), and late (30 days to 1 year).
*86% of patients on clopidogrel and 97% on aspirin at 1-year follow-up.nental obServational Data transitiOnal program) registry(14) of 778 patients treated with the Express2 PES
(Boston Scientific Corporation, Boston, Massachusetts)
reported a 12-month MACE rate (death, MI, and TLR)
of 5.2% and a protocol-defined ST rate of 0.6%. The
combined ARRIVE (The TAXUS Peri-Approval Regis-
try: A Multi-center Safety Surveillance) 1 and ARRIVE
2 (15) registry population of 7,492 patients who under-
went deployment of the TAXUS Express2 PES had a
-year MACE rate (cardiac death, MI, TVR) of 9.5%
nd ARC-defined definite and probable ST rate of 1.8%.
These outcomes in first-generation drug-eluting stents
Taxus Express2, Liberté, and Cypher) suggest that, when
ompared with the XIENCE V, EES might have a better
afety and efficacy outcome both in controlled trials with
trict inclusion/exclusion criteria and in less-selected patient
opulations.
Study limitations. This study was limited by the single-arm
nature of the design and the inherent lack of a control arm
for direct comparison. Lesion characteristics were assessed
and reported by the investigator at the time of the procedure
without core laboratory evaluation of lesion morphology.
Although this was designed as an all-comers registry,
patients were enrolled according to relatively broad inclu-
sion/exclusion criteria. Some inclusion limitations existed
due to the specifications of the Instructions For Use and
device availability. Although consecutive eligible patients
were to be enrolled, it cannot be excluded that the low event
rates might be related to selection bias in favor of low-risk
patients and event under-reporting.
Conclusions
At 30 days, the primary end point of death, MI, and TVR
showed a low rate of 2.7% in this complex patient popula-
tion. This confirmed the acute safety of the XIENCE V
EES.
The 1-year clinical results in the SPIRIT V study indicate
that the use of the XIENCE V EES in a close-to-real-
world population with complex lesions is safe and effective
and results in 1-year MACE, ST, and TLR rates that are
comparable to those of the more-controlled SPIRIT II and
III trials.
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APPENDIX
For a list of participating investigators and institutions,
please see the online version of this article.
